Alan F List1, Zhuoxin Sun2, Amit Verma3, John M Bennett4, Rami S Komrokji1, Kathy McGraw1, Jaroslaw Maciejewski5, Jessica K Altman6, Puneet S Cheema7, David F Claxton8, Selina M Luger9, Ryan J Mattison10, Timothy R Wassenaar11, Andrew S Artz12, Charles A Schiffer13, Mark R Litzow14, Martin S Tallman15. 1. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 2. Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA. 3. Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY. 4. University of Rochester, New York, NY. 5. Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH. 6. Northwestern University, Chicago, IL. 7. Saint John's Hospital, Maplewood, MN. 8. Penn State Cancer Center, Hershey, PA. 9. University of Pennsylvania, Philadelphia, PA. 10. University of Wisconsin, Madison, WI. 11. Waukesha Memorial Hospital, Waukesha, WI. 12. City of Hope National Medical Center, Duarte, CA. 13. Karmanos Cancer Institute, Wayne State University, Detroit, MI. 14. Mayo Clinic, Rochester, MN. 15. Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Abstract
PURPOSE: Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin. METHODS: In a phase III, US intergroup trial, we randomly assigned patients to receive either LEN and EPO alfa or LEN alone following stratification by serum erythropoietin concentration and prior erythropoietin treatment. RESULTS: A total of 195 evaluable patients were randomly assigned: 99 patients to the LEN-EPO alfa cohort and 96 to LEN alone. After four cycles of treatment, the primary end point of major erythroid response (MER) was significantly higher (28.3%) with the combination compared with LEN alone (11.5%) (P = .004). Among 136 patients who completed 16 weeks of study treatment, 38.9% and 15.6% achieved MER, respectively (P = .004). Additionally, minor erythroid response was achieved in 18.2% and 20.8% of patients, for an overall erythroid response rate of 46.5% versus 32.3%. Among LEN nonresponders, 38 crossed over to the addition of EPO alfa with 10 patients (26.3%) achieving a MER. Responses to the combined treatment were highly durable with a median MER duration of 23.8 months compared with 13 months with LEN alone. CONCLUSION: LEN restores sensitivity to recombinant erythropoietin in growth factor-insensitive, lower-risk, non-del(5q) MDS, to yield a significantly higher rate and duration of MER compared with LEN alone (funded by the National Cancer Institute; E2905 ClinicalTrials.gov identifier: NCT02048813).
PURPOSE: Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin. METHODS: In a phase III, US intergroup trial, we randomly assigned patients to receive either LEN and EPO alfa or LEN alone following stratification by serum erythropoietin concentration and prior erythropoietin treatment. RESULTS: A total of 195 evaluable patients were randomly assigned: 99 patients to the LEN-EPO alfa cohort and 96 to LEN alone. After four cycles of treatment, the primary end point of major erythroid response (MER) was significantly higher (28.3%) with the combination compared with LEN alone (11.5%) (P = .004). Among 136 patients who completed 16 weeks of study treatment, 38.9% and 15.6% achieved MER, respectively (P = .004). Additionally, minor erythroid response was achieved in 18.2% and 20.8% of patients, for an overall erythroid response rate of 46.5% versus 32.3%. Among LEN nonresponders, 38 crossed over to the addition of EPO alfa with 10 patients (26.3%) achieving a MER. Responses to the combined treatment were highly durable with a median MER duration of 23.8 months compared with 13 months with LEN alone. CONCLUSION: LEN restores sensitivity to recombinant erythropoietin in growth factor-insensitive, lower-risk, non-del(5q) MDS, to yield a significantly higher rate and duration of MER compared with LEN alone (funded by the National Cancer Institute; E2905 ClinicalTrials.gov identifier: NCT02048813).
Authors: E Hellström-Lindberg; R Negrin; R Stein; S Krantz; G Lindberg; J Vardiman; A Ost; P Greenberg Journal: Br J Haematol Date: 1997-11 Impact factor: 6.998
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: L H Hoefsloot; M P van Amelsvoort; L C Broeders; D C van der Plas; K van Lom; H Hoogerbrugge; I P Touw; B Löwenberg Journal: Blood Date: 1997-03-01 Impact factor: 22.113
Authors: Pierre Fenaux; Uwe Platzbecker; Ghulam J Mufti; Guillermo Garcia-Manero; Rena Buckstein; Valeria Santini; María Díez-Campelo; Carlo Finelli; Mario Cazzola; Osman Ilhan; Mikkael A Sekeres; José F Falantes; Beatriz Arrizabalaga; Flavia Salvi; Valentina Giai; Paresh Vyas; David Bowen; Dominik Selleslag; Amy E DeZern; Joseph G Jurcic; Ulrich Germing; Katharina S Götze; Bruno Quesnel; Odile Beyne-Rauzy; Thomas Cluzeau; Maria-Teresa Voso; Dominiek Mazure; Edo Vellenga; Peter L Greenberg; Eva Hellström-Lindberg; Amer M Zeidan; Lionel Adès; Amit Verma; Michael R Savona; Abderrahmane Laadem; Aziz Benzohra; Jennie Zhang; Anita Rampersad; Diana R Dunshee; Peter G Linde; Matthew L Sherman; Rami S Komrokji; Alan F List Journal: N Engl J Med Date: 2020-01-09 Impact factor: 91.245
Authors: A Toma; O Kosmider; S Chevret; J Delaunay; A Stamatoullas; C Rose; O Beyne-Rauzy; A Banos; A Guerci-Bresler; S Wickenhauser; D Caillot; K Laribi; B De Renzis; D Bordessoule; C Gardin; B Slama; L Sanhes; B Gruson; P Cony-Makhoul; B Chouffi; C Salanoubat; R Benramdane; L Legros; E Wattel; G Tertian; K Bouabdallah; F Guilhot; A L Taksin; S Cheze; K Maloum; S Nimuboma; C Soussain; F Isnard; E Gyan; R Petit; J Lejeune; V Sardnal; A Renneville; C Preudhomme; M Fontenay; P Fenaux; F Dreyfus Journal: Leukemia Date: 2015-10-26 Impact factor: 11.528
Authors: Kathy L McGraw; Ashley A Basiorka; Joseph O Johnson; Justine Clark; Gisela Caceres; Eric Padron; Ruth Heaton; Yukiyasu Ozawa; Sheng Wei; Lubomir Sokol; Alan F List Journal: PLoS One Date: 2014-12-03 Impact factor: 3.240
Authors: Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert Journal: Nature Date: 2015-07-01 Impact factor: 49.962
Authors: U Platzbecker; A Symeonidis; E N Oliva; J S Goede; M Delforge; J Mayer; B Slama; S Badre; E Gasal; B Mehta; J Franklin Journal: Leukemia Date: 2017-06-19 Impact factor: 11.528
Authors: Chen Wang; Kathy L McGraw; Amy F McLemore; Rami Komrokji; Ashley A Basiorka; Najla Al Ali; Jeffrey E Lancet; Eric Padron; Olivier Kosmider; Michaela Fontenay; Pierre Fenaux; Alan F List; David A Sallman Journal: Haematologica Date: 2022-03-01 Impact factor: 9.941